Dyne Therapeutics director Lawrence Klein resigns; shareholders elect new directors and ratify auditor

Dyne Therapeutics, Inc.

Dr. Lawrence Klein resigned from Dyne Therapeutics board effective May 24, 2023, citing no disagreement with the company.
Stockholders elected Joshua Brumm, David Lubner, and Jason Rhodes as Class III directors for three-year terms.
Joshua Brumm received 35,497,922 votes for election; David Lubner received 32,530,452; Jason Rhodes received 28,522,828.
Shareholders ratified Deloitte & Touche as independent auditor for fiscal year 2023 with 44,199,721 votes for, 2,413 against.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Lawrence Klein

member of the Board of Directors

DYN · Dyne Therapeutics, Inc.

Effective: 2023-05-24
Filed: May 25, 2023, 7:59 PM ET

On May 24, 2023, Dr. Lawrence Klein notified Dyne Therapeutics, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Lawrence Klein resigned as member of the Board of Directors at Dyne Therapeutics, Inc..

Action: resigned
Role: member of the Board of Directors

Exact text from the filing

On May 24, 2023, Dr. Lawrence Klein notified Dyne Therapeutics, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company, effective immediately.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Dyne Therapeutics, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-24 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-24

Exact text from the filing

b) The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such matter were as follows: For Against Abstain 44,199,721 2,413 3

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Dyne Therapeutics, Inc. shareholders approved Election of three Class III directors: Joshua Brumm, David Lubner, and Jason Rhodes at the 2023-05-24 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-24

Exact text from the filing

The stockholders of the Company elected Joshua Brumm, David Lubner and Jason Rhodes as Class III directors, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his respective successor has been duly elected and qualified. The results of the stockholders’ vote with respect to such matter were as follows: Name For Withheld Broker Non-Votes Joshua Brumm 35,497,922 6,780,619 1,923,596 David Lubner 32,530,452 9,748,089 1,923,596 Jason Rhodes 28,522,828 13,755,713 1,923,596

View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-024258

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.